FDA
-
-
-
-
-
-
-
SpringWorks Therapeutics (SWTX) Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
-
-
-
-
-
-
-
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
-
-
-
-
-
-
-
FDA approves SpringWorks' (SWTX) mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
-
-
-
-
-
-
-
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
-
-
-
-
-
-
-
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
-
-
-
-
-
-
-
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
-
-
-
-
-
-
-
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
-
322,248 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

